Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (DE:DPOA)
FRANKFURT:DPOA
Holding DE:DPOA?
Track your performance easily
DPOA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.73 - €0.73
Previous Close€0.73
Volume0.00
Average Volume (3M)N/A
Market Cap
€76.44M
Enterprise Value€29.73M
Total Cash (Recent Filing)$88.58M
Total Debt (Recent Filing)$38.84M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Mar 05, 2025EPS Estimate
-€0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding105,354,967
10 Day Avg. Volume100
30 Day Avg. VolumeN/A
Standard Deviation0.19
R-Squared0.19
Alpha0.00702
Financial Highlights & Ratios
Price to Book (P/B)0.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)1.50
P/FCF Ratio0.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit0.24
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
€2.56Price Target Upside250.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Assertio Therapeutics News
PremiumCompany Announcements
Assertio Therapeutics Reports Strong Q3 and Board Changes
PremiumCompany Announcements
Assertio Therapeutics’ Q3 2024 Earnings Overview
Bulls Say, Bears Say
Bulls Say
Growth PotentialWith an established CEO, a strong balance sheet, and cash-generating assets, the Company's poised to return to growth.
Market PositionRolvedon has experienced six consecutive quarters of demand growth and has biologic exclusivity until 2034, providing a long revenue/cash runway.
ValuationASRT shares trade at a 75% discount to peers on a revenue basis, offering an opportunity for investors.
Bears Say
Market CompetitionThe launch by Zydus of a generic was an unfortunate occurrence for the Company’s self-described unicorn product.
Product PerformanceIndocin revenues continuing to diminish, and mixed performances from the other portfolio products, acquisitions will be key to sustaining long-term growth.
Revenue ImpactThe principal source of variance in 2024 revenue is likely to be the evolution of the genericization of Indocin, formerly Assertio's most significant revenue driver.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.06% Insiders
8.21% Mutual Funds
1.45% Other Institutional Investors
82.43% Public Companies and
Individual Investors
DPOA FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was €0.73 and its highest was €0.73 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Currently, no data Available
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is Mar 05, 2025 which is in 111 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Nov 11, 2024. The company reported -€0.028 earnings per share for the quarter, beating the consensus estimate of -€0.043 by €0.015.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -€0.04.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 95,335,630 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of -€0.028 in its last earnings report, beating expectations of -€0.043. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Among the largest hedge funds holding Assertio Therapeutics Inc’s share is Royce & Associates LLC. It holds Assertio Therapeutics Inc’s shares valued at 94K.
---
Assertio Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€2.56 (250.64% Upside)
€2.56 (250.64% Upside)
Blogger Sentiment
Bullish
DE:DPOA Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.92%
12-Months-Change
Fundamentals
Return on Equity
-42.36%
Trailing 12-Months
Asset Growth
-27.37%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
---
DPOA Earnings Call
Q3 2024
0:00 / 0:00
---
DPOA Stock 12 Month Forecast
Average Price Target
€2.56
▲(250.64% Upside)
Technical Analysis
Assertio Therapeutics
―
Aldeyra Therapeutics
―
TuHURA Biosciences
―
Relmada Therapeutics
―
Aileron Therapeutics
―
Best Analysts Covering DPOA
1 Year
1 Year Success Rate
7/31 ratings generated profit
1 Year Average Return
-26.85%
reiterated a buy rating 2 days ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 22.58% of your transactions generating a profit, with an average return of -26.85% per trade.
---